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Abstract 
REACTIVE GLIOSIS FOLLOWING HIPPOCAMPAL IMPLANTATION: 
A biocompatibility evaluation of five materials. 
Karl A. Lozanne (Sponsored by Dennis D. Spencer). Department of Neurosurgery, Yale 
University School of Medicine, New Haven, CT. 
The present study aimed to determine the biocompatibility of several materials proposed 
for the development of a novel intracranial biosensor. The glial reaction induced by short¬ 
term (14 day) and long-term (90 day) implantation of potential biosensor substrates, 
namely carbon, silicon, gold, platinum and Pyrex, into the hippocampus was measured 
and characterized. Needle shaped implants of each material, 0.5 mm in diameter, were 
implanted into the hippocampi of adult rats for 14 or 90 days. Glial fibrillary acidic 
protein immunohistochemistry coupled with mean optical density (MOD) measurements 
were used to determine the level of reactive gliosis following implantation. The extent of 
gliosis varied depending on the implant type and was lowest for platinum followed in 
increasing level by gold, carbon, silicon, and Pyrex. The glial reaction decreased in 
volume over time for each substrate except Pyrex, leaving behind a thin, porous glial 
membrane at the brain-implant boundary. We conclude that platinum and gold are the 
best substrates for a chronically implanted neural biosensor, but that carbon and silicon 
are also suitable. We caution against the long-term use of Pyrex as a substrate because a 
chronic glial reaction develops following its implantation. 
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Extracellular concentrations of neurotransmitters reflect the balance between the rate of 
neurotransmitter release from presynaptic vesicles and the rate of uptake into adjacent 
neurons and glia. Microdialysis, a technique which measures the extracellular 
concentrations of neurotransmitters or other compounds in the brains of awake, 
ambulatory animals, following the stereotactical introduction of microdialysis probes into 
specific brain regions, has allowed greater insight into the biochemical milieu of the brain 
(Benveniste 1989; Benveniste, Hansen et al. 1989; Benveniste and Huttemeier 1990; 
Maggs, Borg et al. 1997; Chapman 1998), When coupled with models of ischemia, 
trauma, and seizure disorders, microdialysis has provided insight into the local 
biochemical derangement that accompanies these CNS disorders (Benveniste, Hansen et 
al. 1989; Chapman 1998). 
In 1991, the first human in vivo biochemical measurements of the effects of spontaneous 
seizures in the human brain extracellular environment were performed at Yale by 
attaching a microdialysis membrane to the depth electrodes of patients undergoing 
evaluation for surgically remediable, medically intractable epilepsy (During 1991). 
Besides helping to establish microdialysis use in the study of human CNS disease, this 
and subsequent studies helped identify adenosine, glutamate, GABA, lactate and pH as 
mediators involved in seizure onset, spread, and spontaneous arrest (During and Spencer 
1992; During and Spencer 1993; During, Fried et al. 1994). 
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Despite the insight provided by these studies, the measurements obtained have been 
limited in scope mainly due to the limitations of off-line microdialysis techniques. 
Microdialysis relies on a rapid exchange of small molecules across a semipermeable 
membrane (typically 10-30 mm long in humans) that is implanted into an extracellular 
space several orders of magnitude larger than the dimension of the synaptic cleft. 
Furthermore, the time resolution (2-5 mins) is orders of magnitude slower than synaptic 
events (Chapman 1998). Considering these limitations, investigators have been led to 
seek more accurate and detailed information to answer the following questions. Do 
concentrations of identified mediators involved in seizure activity fluctuate in the 
immediate moments prior to seizure onset? Are there threshold levels in the 
concentration of these mediators at which an ictal event is imperative? What influence 
do the concentrations and fluctuations of glucose and CF have on seizure onset, spread, 
and spontaneous arrest? What role does pH play? Answers to these questions require 
continuous measurement of the dynamic changes in the extracellular biochemical 
environment of a seizure focus. Despite the usefulness and continued refinement of brain 
microdialysis technique (Benveniste 1989), new technology is necessary to accurately 
characterize the peri-ictal molecular environment. 
Statement of Purpose 
In collaboration with the Dept, of Engineering at Yale, a project to develop an 
electromolecular sensing probe that can measure the dynamic changes in 
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neurotransmitters, lactate, pH, O2, glucose and other molecules simultaneously with 
electrical variations was begun. The present study is a preliminary evaluation of 
biocompatibility for some of the materials proposed as the substrate for this biosensing 
device. In particular, this study measured the extent of reactive gliosis in the 
hippocampus incurred by implantation of carbon, silicon, gold, platinum and Pyrex, 
materials that are well established in microelectronics. 
Reactive gliosis 
In response to CNS trauma of any kind, including the introduction of foreign material, 
there is a rapid, local, multicellular response dominated by astrocyte proliferation 
(Kumar, Robbins et al. 1999). During this reactive astrocytosis (a.k.a. reactive gliosis), 
astrocytes proliferate and increase in size, their cytoplasmic processes become larger and 
more tortuous, and there is a substantial increase in the number of intermediate glial 
filaments and in glial fibrillary acidic protein (GFAP) content (Eng 1985; Arnold, Franz 
et al 1996). Immunohistochemical methods for the detection of GFAP, the major protein 
constituent of glial intermediate filaments in differentiated astrocytes, have been 
extensively used for the study of reactive gliosis (Eng, Smith et al. 1985). 
Previous studies relying on conventional techniques, including cell counting and 
proximity of neurons, have revealed an inconsistent pattern of reactive gliosis following 
the implantation of foreign material into the brain. This variation has been attributed to 
the trauma of implantation and the toxicity of the materials implanted (Stensaas and 
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Stensaas 1976; Stensaas and Stensaas 1978; Del Bigio and Bruni 1986; Benveniste and 
Diemer 1987; Edell, Toi et al. 1992; Schmidt, Horch et al. 1993; Menei, Croue et al. 
1994; Yuen and Agnew 1995; Emerich, Tracy et al. 1999). In the present study, an 
attempt at an objective quantification of the reactive gliosis following hippocampal 
implantation of carbon, silicon, gold, platinum and Pyrex is undertaken by combining 
GFAP iinmunohistochemistry with optical density measurements. 
Materials and Methods 
Implant Materials 
Uncoated pure platinum wire and gold wire, .5 mm in diameter, were purchased from 
World Precision Instruments, Inc. (Florida, USA). Carbon was purchased as .5 mm 
diameter mechanical pencil lead from Staples. Silicon and Pyrex pieces, .5 mm in 
diameter, were obtained from the Electrical Engineering Department at Yale College. 
One end of each implant was cut, broken, or ground into a needle-shaped edge. 
Implantation 
Prior to implantation, each implant was bathed in ethanol and allowed to air dry for 5-10 
minutes. Adult male Sprague-Dawley rats (Charles River Laboratories, MA, USA), 
weighing 250-300 g were anesthetized with an injection of Ketamine (60 mg/kg, IM) 
followed by Pentobarbital (20 mg/kg, IP) and mounted on a small animal stereotaxic 
instrument (David Kopf Instruments, CA, USA). Under aseptic conditions, a midline 
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incision was made in the scalp and the bregma was identified. With the aid of a burr-drill, 
two small craniotomies were made 3.6 mm posterior to the bregma, bilaterally at 2.7 mm 
from the midline. One needle shaped implants was implanted into each hippocampus by 
slowly (1 mm/ 30 s) advancing the implant 3.8 mm deep into the burr hole. The 
externalized portion of the implants were stabilized against the skull by application of 
instant adhesive glue and accelerator. For additional stabilization, once the glue was dry, 
a small screw was inserted into the skull 2 mm posterior to the lambda and the wound 
was covered with denture resin. To simulate trauma alone, a gold implant was implanted 
in the animal’s hippocampus using the technique described above, tapped 10 times and 
extracted prior to glue and denture resin application. 
Each animal received 100,000 lU/kg S.Q. Flocillin antibiotic immediately following the 
procedure and was subsequently housed in a single animal cage maintained in a 
temperature- and humidity-controlled colony room. Post-surgical analgesia consisted of 4 
days of Tylenol 0.32 mg/ml via water bottle. Food and water were available ad lib during 
the experiment The Yale University Institutional Animal Care and Use Committee 
approved all procedures. 
Histology 
Animals were sacrificed at 14 and 90 days following implantation Following a lethal 
intraperitoneal injection of pentobarbital of at least 150 mg/kg, rats were transcardially 
perfused with an aldehyde solution containing 4% paraformaldehyde with the aid of a 
Masterflex pump (Cole-Parmer Instrument Company, IL, USA). The implants were 
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extracted and intact brains were then removed and immersed in the same fixative for 1 to 
3 days. One day prior to sectioning, the brain was immersed in a 30% sucrose solution. 
Using a microtome, frozen 60 |im thick coronal sections of the brain areas that previously 
contained the implants were cut and mounted on glass slides. 
Immunohistochemistry 
After thorough washing in 0.1M Tris-HCl buffer containing 0.3% Triton X-100 (Sigma), 
sections were exposed to a block solution containing 2% bovine serum albumin (Sigma) 
in the washing solution for approximately 1 hour. Sections were then exposed to a rabbit 
primary monoclonal antibody directed against glial fibrillary acidic protein (GFAP 1:500, 
Sigma) overnight at 4° C. Following washing, sections were incubated with anti-rabbit 
secondary biotinylated antibody (Sigma) at room temperature for 1 h and then an 
avidimbiotin enzyme complex (Vector Labs, CA, USA) for 1 h. The catalyzed signal 
amplification was employed to enhance the immunostaining. After rinsing, the reaction 
was developed using 3,3’-diaminobenzidine tetrahydrochloride (Sigma) and hydrogen 
peroxide at room temperature. Sections were then dehydrated and mounted in DPX 
(Sigma). 
Optical Density Measurements 
Pictures of each immunostained slide were taken and converted to gray scale digital 
images using an Olympus Magnafire digital microimaging system (Olympus America 
Inc., NY, USA). Using Scion Image software (Scion Corp.), mean optical density 
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2 
(MOD) measurements were taken of 2000 (am regions in 1) the corpus callosum and; 2) 
three zones adjacent to the implant track- zone 1 from implant boundary out 100 pm, 
zone 2 100 pm to 200 pm from boundary, zone 3 200 pm to 300 pm from boundary 
(Figure 1). For each animal, ratios of MOD in the corpus callosum to MOD in each of 
the three zones were calculated. The average of the mean optical density ratios (avg. 
MODR) for each study group was then calculated and used in between group 
comparisons. For control and trauma samples, since no implant track was available to 
determine the three zones, the MOD of four 2000 pm2 regions corresponding to the 
hippocampal implant sites were taken and averaged. This average was then used to 
calculate a ratio of mean optical density in the corpus callosum to mean optical density in 
the hippocampus. Using the method of calculating mean optical density ratios mentioned 
above, higher MOD ratios correspond to higher levels of reactive gliosis. MOD ratios, 
rather than the absolute MOD values, were used for comparisons to adjust for varying 
intensities of staining between samples. 
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Figure 1. Calculation of mean optical density (MOD) at zone 1, zone 2, and zone 3. 
MODs were measured for a 100mm x 200mm area of the corpus callosum and for each of three zones 
adjacent to the implant track. Ratios for each zone were calculated using the following equation 
MOD Ratio= MOD Corpus 
MOD Zone 
No statistical analysis of mean optical density measurements was undertaken because of 
the low number of animals that were included in the study. Therefore, conclusions are 
drawn mostly from histological analysis with average MOD ratio measurements used to 
confirm gross histological findings. 
The author conducted all animal surgeries, preparation of reagents, 
immunohistochemistry, and optical density measurements. The author performed most 
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transcardial perfusions and microtome sectioning of tissue on his own with help from 
Dolores Montoya of the Dept, of Neurosurgery when available. 
Results 
No overt neurological changes were seen in the rats following implantation. There were 
no deaths or signs of infection throughout the study period Nine animals lost their dental 
cement caps prior to completing their study interval. Included in the final analysis were 
1) animals who maintained an intact dental cement cap throughout the study period; 2) 
tissue slice preparations that showed immunocytochemical staining adequate for 
morphological and optical density evaluation (i.e, GFAP specific immunoreactivity with 
good astrocyte morphology throughout hippocampus and corpus callosum). Evaluation 
of intermediate study intervals (30 and 60 day) were limited by technical difficulties. 
Controls 
Small, GFAP immunoreactive cells were found diffusely throughout the brain slices but 
were most prominent within the cortex and along the corpus callosum. Within the 
hippocampus, the polymorphic layer of the dentate gyrus consistently stained darker than 
adjacent regions, however, no distinct clustering of GFAP immunoreactive cells were 
seen within the hippocampus (Figure 2). This pattern of GFAP immunoreactivity in 
normal adult rat brains is consistent with previous studies (Benveniste and Diemer 1987; 
Gammer, Tansey et al. 1990). 
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Figure 2. Immunohistochemical staining for glial fibrillary acidic protein (GFAP) in hippocampus of 
control specimen. Note the darker staining polymorphic layer of the dentate gyrus (PoDG) with 
small GFAP imniunoreactive astrocytes (arrows) hut no distinct clustering of cells (GFAP 1:500 
100X). 
14 day implants 
Similar to control slices, the polymorphic layer of the dentate gyrus in implant specimens 
stained darker than adjacent regions. For all implant types, however, GFAP 
imniunoreactive cells clustered around the site of implantation. In particular, GFAP 
immunoreactivity was most prominent along the implant-brain boundary (Figure 3). 
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Figure 3. GFAP immunoreactive astrocytes at implant-brain boundary 14 days post-implantation. 
Images show reactive gliosis with clustering of large astrocytes around site of implantation (arrows). 
Note the less intense reactive gliosis for the platinum and gold implants (A, B). Also note the 
clustering of large astrocytes and pockets of hemorrhage where trauma was simulated (F, curved 
arrow) (GFAP 1:500 100X). 
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In general, implant-brain boundaries revealed large astrocytes immediately adjacent to 
the implant tracks. Hypertrophic processes originating from these astrocytes could be 
seen extending towards the site of implantation. At increasing distances from the implant 
track, the size of the astrocytes and their processes decreased with a return to the typical 
sizes seen in control specimens at distances greater than 275-300 pm (Figure 4). 
Figure 4. Reactive gliosis close to the site of gold implantation (implantation site to the left of image). 
Large astrocytes with hypertrophic processes (white arrow) can be seen closer to the site of 
implantation with decreased levels of reactive gliosis and decreases in the size of astrocyte processes 
at increasing distance from the implant site (black arrow). 
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Levels of GFAP immunoreactivity varied according to the implant type (platinum, gold, 
carbon, silicon, or Pyrex implant). Of the materials studied, platinum appears to have the 
least dense level of GFAP immunoreactivity at the boundary and adjacent regions. 
Despite the characteristic increased density and clustering of GFAP immunoreactive cells 
seen in implanted specimens, no distinct, confluent layer of astrocytes is seen at the 
platinum-brain boundary. Unlike platinum, the Pyrex-brain boundary is characterized by 
densely packed large astrocytes forming a wall approximately 10 to 25 pm thick around 
the implant. Close examination of the Pyrex-brain boundary revealed that the apparent 
capsule is porous, with some gaps measuring greater than 50 pm in diameter (Figure 5). 
The remaining implant types showed levels of GFAP immunoreactivity between those 
seen for platinum and Pyrex, with the level for gold appearing the most similar to that for 
platinum and the level for carbon being the most similar, but not as heavy, as that for 
Pyrex. 
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Figure 5. Increasing magnification of 
glial barrier at Pyrex-brain implant 
boundary. Note the porosity of the 
barrier. 
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In areas of the hippocampus where trauma was simulated, a diffusely increased level of 
GFAP immunoreactivity was apparent. Clustering of large GFAP immunoreactive cells 
could be seen, often accompanied by pockets of hemorrhage (Figure 3. F). 
Measurements of mean optical density ratios (MODRs) corroborated the gross 
observations for the 14-day implants and confirmed that platinum was the implant type 
incurring the least amount of reactive gliosis (average MODR in zone 1= 1.01; Table 1). 
Platinum was followed in increasing level of average MODR by gold, carbon, silicon, 
and Pyrex (average MODRs in zone 1 of 1.06, 1,11, 1.12, and 1.16, respectively) All 
implant types, including simulated trauma, displayed average MODRs greater than 
controls. Platinum-implanted specimens had an average MODR comparable to that of 
simulated trauma specimens (1.01 and 1.05 for platinum and trauma respectively). 
MODRs decreased successively at 100-200 pm (Zone 2) and 200-300 pm (Zone 3) 
radius from the brain-implant boundaries for each implant type. Despite this decrease, the 
average MODRs at 200-300 pm radius for each implant type is still higher than that of 
control. 
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Table 1. Average mean optical density ratios for each of the zones adjacent to the implant-brain 
boundary at 14 and 90 days post-implantation. 
90 day implants 
In general, the levels of GFAP immunoreactivity seen in the hippocampus at 90 days 
post-implantation appear lower than that seen at 14 days post-implantation. The reaction 
immediately surrounding the implants remained dense but began to decrease in total area. 
Clusters of large astrocytes with hypertrophied processes can still be seen immediately 
adjacent to implant tracks but small astrocytes, consistent in size with those seen in 
control specimens, dominated regions as close as 200 pm from the implant-brain 
boundary (Figure 6). 
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Figure 6. GFAP immunoreactive astrocytes at implant-brain boundary 90 days post-implantation. 
Large astrocytes are more localized to areas immediately adjacent to implant site compared to 14 
day counterparts (white arrows). A densely packed thin layer of astrocytes at each implant-brain 
boundary appears to form a barrier between brain and implant (black arrows). Note the small area 
of clustered astrocytes still apparent at the site of simulated trauma (F, curved arrow) (GFAP 1:500 
100X). 
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Platinum and gold, once again, appeared to incur the lowest levels of reactive gliosis with 
Pyrex on the opposite side of the spectrum. The increased duration of implantation, 
however, appeared to allow time for a more consolidated, yet thinner, boundary of 
reactive astrocytes for each implant type. Despite this, the apparent “barriers” which 
developed continued to display the porosity seen with the 14-day implants. 
Where trauma was simulated, increased levels of GFAP immunoreactivity and large, 
hypertrophied astrocytes were still observed at 90 days. However, in contrast to their 14- 
day counterparts, the clusters of large GFAP immunoreactive cells seen in 90-day post- 
simulated trauma specimens appeared to be more concentrated, spanning smaller areas. 
Furthermore, at 90 days, signs of hemorrhage were no longer apparent in any of the 
studied trauma specimens. 
Average MODRs for our long-term implants confirmed most of our gross observations. 
The 90-day average MODRs within 100pm (Zone 1) of the implant track for each of the 
implant materials, except Pyrex, decreased relative to the 14-day measurements (Table 1; 
Figure 7). This decrease was also seen in the simulated trauma specimens. Similar 
decreases in average MODR were seen at 100-200pm (Zone 2) and 200-300pm (Zone 3) 
for all implant materials, except Pyrex, whose MODR levels in the more distant zones 
remained similar to levels seen at 14 days. 
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Platinum proved once again to be the least reactive material with an average MODR 
within 100 pm (Zone 1) of 0.66. Pyrex showed the highest amount of reactive gliosis 
with an average MODR of 1.32. This time, however, platinum was followed in increasing 
reactivity by gold, silicon, and then carbon (average MODRs of 0.92, 1.03, 1.04, for gold, 
silicon, and carbon respectively). For platinum in particular, the average MODRs in the 
immediately adjacent zone was comparable to that seen for control specimens (0.66 for 
platinum versus 0.86 seen in controls) and substantially lower than that seen for 
simulated trauma (0.66 versus 0.91). Pyrex was the only implant type for which an 
increase in the average MODR for the long-term implant, when compared to the short¬ 
term implant, was seen (1.32 up from 116). 
Figure 7. Average mean optical density ratios (MODRs) at 90 days post-implantation relative to 14 
days for each zone adjacent to implant-brain boundary. The average MODRs are plotted on the y- 
axis with zones 1, 2, 3 for each implant type adjacent to each other. The negative deflection at 14 
days for zone 1 of the Pyrex implant reflects an increase in average MODR at 90 days relative to 14- 
day levels. 
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Discussion 
A critical factor in the development and long-term effectiveness of implantable 
intracranial devices is the development of appropriate biomaterials that directly contact 
the nervous tissue. Previous studies have revealed that while many materials are non¬ 
reactive and produce little to no parenchymal alterations, others induce varying degrees 
of reactive changes through local toxic effects (Stensaas and Stensaas 1976; Stensaas and 
Stensaas 1978). The present study is consistent with these findings. 
We acknowledge the difficulty in making conclusions regarding the long-term platinum 
and gold implants considering the low number of specimens that underwent complete 
evaluation with these implant types. Difficulties with maintaining intact implants in vivo 
throughout the study periods and technical difficulties with immunohistochemistry 
resulted in small study groups. However, we feel justified in drawing the following 
conclusions in that the differences in the histological and mean optical density evaluation 
between these and the other implant types was not only striking, but also consistent with 
the differences seen in the short-term implants. 
We demonstrate that implantation of carbon, silicon, gold, platinum or Pyrex into 
hippocampus induces a local glial reaction present at 14 days that is generally 
characterized by the accumulation of large astrocytes clustering into a porous glial barrier 
at the implant-brain boundary. Platinum showed the least amount of reactive gliosis 
followed by gold, carbon, silicon, and Pyrex. The area of gliosis decreased in volume 
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and localized to the implant-brain boundary for each implant type except Pyrex. 
Complete resolution of reaction can be seen within 100 pm for the platinum and gold 
implants, and within 300 pm of the silicon and carbon implants at 90 days. The reactive 
gliosis induced by platinum and that induced by gold, appear to be due in large part to the 
trauma of implantation rather than intrinsic toxicity. For silicon, carbon, and Pyrex, 
intrinsic characteristics of the material implanted, in addition to the trauma of 
implantation, appear to contribute to the level of reactive gliosis. 
Using persistence of reactive gliosis at >15 pm from the implant-brain barrier at 90 days 
post-implantation as a measure of toxicity, platinum and gold appear to be non-toxic, 
while silicon and carbon show slight toxicity. Pyrex appears to be toxic to brain tissue 
since, unlike the other materials, no resolution to the reactive gliosis incurred by Pyrex 
implantation was seen at 90 days. 
Implantation of foreign material induces local gliosis present at 14 days. 
All studies looking at biocompatibility of implanted materials have shown that an acute 
local glial reaction occurs at the site of implantation. Collias and Manuelidas (1957), two 
weeks after implanting non-toxic multilead electrodes into cats, noted swollen astrocytes 
surrounding the implants. Similar results were reported following implantation of plastic 
needles (araldite) (Stensaas and Stensaas 1976), microdialysis tubes (Benveniste and 
Diemer 1987), and polymer microspheres (Emerich, Tracy et al. 1999) into the brain. 
The present study is consistent with these findings. At 14 days, each of the implanted 
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materials exhibited a local glial reaction characterized by large astrocytes and 
hypertrophic astrocyte processes. 
It is conceivable that the acute glial reaction is largely due to the trauma of implantation. 
During implantation, tissue must be torn, cut, stretched, or compressed by the material 
being introduced. Non-smooth implant surfaces may contribute to these processes. 
Tearing, in particular, could cause damage to cell membranes causing death and release 
of intracellular mediators of inflammation and gliosis. In addition, damage to capillaries 
as the implant traverses the brain parenchyma can lead to microhemorrhages with 
resultant release of additional inflammatory factors and potential damage to parenchymal 
cells. Edell, Toi, et al. (Edell, Toi et al. 1992) propose that any feature of an implant that 
is larger than a few tens of angstroms may catch on filamentous structures which could 
cause propagation of forces into adjacent structures and result in tissue damage. 
Considering this extreme size demand, even nonreactive implants, should be expected to 
induce, at least, a minimal reaction acutely. Each material implanted in the present study 
induced a glial reaction that was visible at 14 days. Thus, a baseline level of reactive 
gliosis can be attributable to the trauma of implantation, with variations in reaction above 
this level attributable to intrinsic toxic characteristics of the implanted material. 
Reaction leads to the production of a glial membrane surrounding the implant. 
The implant boundary for each of the implants in this study is characterized by densely 
packed large astrocytes forming a glial barrier. This GFAP- rich zone has been noted in 
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previous studies (Schmidt, Horch et al. 1993; Menei, Croue et al. 1994; Liu, McCreery et 
al. 1999; Kristensen, Noraberg et al. 2001) and is frequently referred to as a capsule. 
Edell, Toi et al. found 5 to 75 pm thick, and sometimes up to 250 pm thick glial 
“capsules” around insulator-coated metal conical shafts that were inserted into cortex 
(Edell, Toi et al. 1992). On the other hand, Liu, McCreery et al. found negligible 
encapsulation around exposed electrode tips implanted into cortex (Liu, McCreery et al. 
1999). Consistent with the variation seen in previous studies, our study shows that the 
GFAP-rich zone at the implant boundary varies in thickness depending on implant type. 
This variation reflects the different intrinsic toxicity of the various materials. 
Our study further suggests, that this boundary is not stable. The GFAP-rich zone 
surrounding platinum implants was never greater than 7 pm thick for both short-term and 
long-term implants. However, the GFAP-rich zone surrounding Pyrex, showed a 
maximum thickness of 37 pm (range 30 to 37 pm) at 14 days and a maximum thickness 
of 30 pm (range 25 to 30pm) at 90 days. Result from the study by Liu, McCreery et al. 
indicates that the implant-tissue interface may change from day-to-day over the first 1-2 
weeks, week-to-week for 1-2 months, and become quite stable thereafter. A variety of 
mechanisms may contribute to this initial instability. Microtrauma, from movement of 
the brain relative to the implant, or vice versa, is an explanation that must be considered. 
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The glial membrane is porous. 
Close examination of the GFAP-rich zone surrounding Pyrex implants in our study 
revealed that the glial barrier is porous, with some gaps measuring greater than 50pm in 
diameter. For this reason, we’ve refrained from calling the glial barrier a “capsule”, since 
it is not confluent and bears more of a resemblance to a semipermeable membrane than a 
capsule. The porosity of this glial membrane is relevant to the development of any 
biosensing device because direct communication between the sensing elements and the 
extracellular fluid is essential. 
Reactive gliosis decreased over time for all implants except Pyrex. 
Though gliosis is still seen at 90 days post-implantation for all materials studied, the 
volume of the reaction decreased substantially for platinum and gold implants, decreased 
moderately for silicon and carbon implants, but remained constant for Pyrex implants. 
For the least reactive materials, the glial reaction resolved except for a thin layer of 
astrocytes at the implant-brain boundary. Consistent with our study, Stensaas and 
Steensaas, in their histopathologic evaluation of several materials implanted into the 
cerebral cortex for up to 723 days, found a narrow zone of astrocyte processes at the 
implant surface of non-reactive materials (Stensaas and Stensaas 1978). The finding at 90 
days of astrocyte clustering where trauma was previously simulated suggests that the 
thin, porous glial membrane seen surrounding the least reactive implants (platinum and 
gold) is likely a remnant of the reaction to the trauma of implantation- a glial scar, and 
not representative of an active glial reaction to the implant. 
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Pyrex, on the other hand, displayed no relative change in the volume of reaction 90 days 
after implantation. The level of reaction is substantially greater than that seen 90 days 
following simulated trauma. This suggests that an active reactive gliosis, not only glial 
remnants of implantation trauma, persists after long-term implantation of Pyrex. Intrinsic 
toxicity of Pyrex is the likely cause of this persistent reaction. 
On building a biosensor. 
From the present preliminary biocompatibility evaluation, we conclude that platinum and 
gold are the best substrates for a chronically implanted intracranial biosensor. Silicon 
and carbon appear to be suitable materials for direct contact with brain tissue but the use 
of Pyrex is cautioned against since its direct contact with brain tissue induces a chronic 
reactive gliosis. If Pyrex is to be used in the final construct, its apposition with brain 
tissue should be avoided. 
We realize that the biocompatibility of any implantable device is not limited to non¬ 
toxicity, and that investigations into the whole behavior of the implant in its biological 
environment will need to be undertaken. Additional considerations include the long-term 
effect of the brain on the implant and, conversely, the long-term effects of the implant on 
the brain and other systems. In particular, the corrosive effects of the in vivo 
environment and enzymatic breakdown of device components need to be analyzed. 
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Furthermore, the effect of chronic device implantation and use on the blood brain barrier, 
metabolism, biochemistry, as well as morphology of the CNS must be studied. 
It is feasible, considering present sensor and microelectronic technologies, and the 
availability of biocompatible materials, to have an implantable construct that would allow 
accurate, real-time measurements of neurotransmitters, lactate, glucose, pH, O2, and other 
molecules. We imagine that in the future, such a device would not only be used as a 
diagnostic tool but, when coupled with a microinfusion mechanism, may provide a 
therapeutic alternative in the treatment of several CNS diseases by allowing the 
recreation of homeostasis at the site of CNS pathology 
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